This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Once Hated, Now Loved

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK ( TheStreet) -- Investors are like most TV watchers, always changing channels, Jim Cramer told his "Mad Money" TV show viewers Thursday. He opined about a multitude of stocks that were once hated but are now loved as investors have once again changed their minds.

No stock illustrates this move better than Facebook (FB), a stock Cramer owns for his charitable trust, Action Alerts PLUS . Cramer said that after the worst IPO in history, Facebook has emerged as the king of mobile and social advertisers. He's still a buyer of Facebook, along with Google (GOOG).

Other sectors that are getting a second look include travel, thanks to TripAdvisor (TRIP), and the airlines, with US Airways (LCC) leading the charge.

Biotech remains a hot sector, with Cramer recommending Celgene (CELG) and Regeneron (REGN) as just two of many faves. He was also bullish on housing, despite disappointments from D.R. Horton (DHI). He said that news won't affect ancillary housing stocks such as Home Depot (HD) and Restoration Hardware (RH).

Other Cramer faves include the autos, banks and oil and gas stocks, along with some technology and semiconductor names. Cramer even had kind words for Starbucks (SBUX) and Dunkin' Brands (DNKN).

Executive Decision: Tarek Sherif

In the "Executive Decision" segment, Cramer spoke with Tarek Sherif, founder, chairman and CEO of Medidata Solutions (MDSO), the cloud computing provider to the health care industry that's seen it shares rise by 30% since Cramer last spoke with Sherif just six weeks ago.

Sherif said the Food and Drug Administration is mandating that the industry change the way it performs clinical trials, and Medidata is the prime beneficiary of that mandate. He said by using modern cloud technology, Medidata is driving value by improving the quality of trials with less risk and helping to bring better drugs to market faster.

Sherif said clinical trials are still largely in the early stages of using technology, but those that have embraced the technology are getting through their trials faster. He said Medidata has a terrific business model where 80% to 90% of its revenue stems from repeat customers.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs